CID1231538

CAS No. 354126-20-8

CID1231538( —— )

Catalog No. M24307 CAS No. 354126-20-8

CID1231538 is a potent?GPR35?antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 125 In Stock
10MG 200 In Stock
25MG 402 In Stock
50MG 593 In Stock
100MG 845 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CID1231538
  • Note
    Research use only, not for human use.
  • Brief Description
    CID1231538 is a potent?GPR35?antagonist.
  • Description
    CID1231538 is a potent?GPR35?antagonist.
  • In Vitro
    GPR35 has gained special consideration as a result of its association with many diseases including type-2 diabetes, nociceptive pain, inflammation, mild mental retardation syndrome, metabolic disorders, and gastric cancer.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    GPR
  • Recptor
    GPR35
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    354126-20-8
  • Formula Weight
    524.05
  • Molecular Formula
    C26H22ClN3O3S2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (95.41 mM)
  • SMILES
    O=C(NC1=CC=C2N=C(SCC3=CC=C(Cl)C=C3)SC2=C1)C4=CC=CC=C4C(N5CCOCC5)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Abdalhameed MM, et al. Structure-activity relationships of benzothiazole GPR35 antagonists. Bioorg Med Chem Lett. 2017;27(3):612-615.
molnova catalog
related products
  • 2-(pentylsulfanyl)py...

    2-(pentylsulfanyl)pyrimidine-4,6-diol is a novel GRP84 agonist.

  • Ramatroban

    Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis.

  • Myristyl nicotinate

    Myristyl nicotinate is an ester prodrug being developed for delivery of nicotinic acid (NIC) into the skin for prevention of actinic keratosis and its progression to skin cancer.